Hafnium oxide nanoparticles

氧化铪纳米制剂

Report date: 2026/05/23 20:00:57

Base Information

Drug NameHafnium oxide nanoparticles
Drug Alias NameHensifyNBTX-3NBTXR-3PEP-503JNJ-90301900 +[6] 
ClassificationSmall molecules
Mechanisms of ActionRadiography enhancersStimulator of interferon genes modulatorsFree radicals stimulants
TargetsStimulator of interferon genesFree radicals
Therapy Area/IndicationsSkin MelanomaUrinary Bladder NeoplasmsProstatic Neoplasms +[18] 
Global Approved IndicationsSarcoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2019/04/04
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanobiotix SA
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Enterprise Innovation IncJohnson & Johnson (China) Investment LtdThe University Of Texas MD Anderson Cancer Center +[7] 
Inactive CompaniesN/A
Active IndicationsSkin MelanomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[16] 
Inactive IndicationsProstatic NeoplasmsRectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A